Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis

NCT05583344 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT05583344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 2, 2023
Completion date
September 18, 2026
Enrollment
284 (actual)
Sites
170

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease, nonalcoholic fatty liver disease